The effect of cannabidiol (300 mg) on fear conditioning.

- Male or female volunteers between 18 and 30 years.

- Judged to be in good physical and mental health on the basis of the medical history according to self-report.

- Have a normal binocular acuity, corrected or uncorrected.

- Female participants must declare they are on reliable birth control.

- History of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study.

- Present any other conditions in that in the investigators’, the subjects’ personal or the study physicians’ opinion may confound the results of the study.

- History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis.

- Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study.

- Current cardiac disease and/or history of cardiac disease.

- Known hypersensitivity to CBD.

- History of cannabinoids exopsure with adverse reactions.

- History of severe allergy or general drug hypersensitivity.

- History of abuse or current regular use of cannabis more than once a week.

- Usage of psychoactive drugs in the four weeks prior to the study.

- Current use of drugs of abuse or indications (urine screening)

- History of epilepsy.

- Pregnancy, i.e., a positive β-HCG urine test.

- Lactating.

- Reduced startle reactivity, defined as no discernable response in at least 3 out of the 12 startle stimuli presented at screening.